M&A Deal Summary |
|
|---|---|
| Date | 2023-12-18 |
| Target | Visant Medical |
| Sector | Medical Products |
| Buyer(s) | Amring Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Raymond James - Investment Banking (Financial) Wilson Sonsini Goodrich & Rosati (Legal) |
SEARCH BY
Amring Pharmaceuticals is a pharmaceutical company that provides value brands and niche generics to the market. The company is part of Sever Life Sciences, BV and is partnered with well-established global biopharmaceutical companies. Amring is uniquely positioned to leverage its partners’ expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-12-02 |
LYSTEDA
Switzerland LYSTEDA is a non-hormonal therapy created specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). |
Buy | - |
